ArticleHealth affairs (Project Hope)2023
Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.
Article in Health affairs (Project Hope), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Community-level determinants of buprenorphine provider availability: A ZCTA-level (zip code tabulation area) analysis.Drug and alcohol dependence reports · 2026Article
- Inpatient initiation of long-acting injectable buprenorphine for adolescents and young adults with opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- How should low-threshold and primary care clinics prepare to provide long-acting injectable buprenorphine? A qualitative implementation study of patient and staff perspectives.Research square · 2026Article
- Abandonment of Prescribed Buprenorphine for Opioid Use Disorder, 2020-2024.JAMA network open · 2026Article
- Prior Authorization Requirements in Medicare Advantage and County Social Vulnerability.The American journal of managed care · 2026Article
- Health System Integration and Prior Authorization in Medicare Advantage.Health services research · 2026Article
- Enhancing Compliance Through Local Anesthesia in Extended-Release Buprenorphine Therapy: A Report of Two Cases.Cureus · 2026Article
- Buprenorphine Microinduction Treatment in Tri-Diagnosis Patients with Opioid Use Disorder and Chronic Non-Cancerous Pain.Current pain and headache reports · 2026Review
- Subgroup identification of disparities in buprenorphine discontinuation in opioid-use disorder: A Virtual Twins machine learning approach using nationwide United States claims data, 2006-2022.PLOS mental health · 2026Article
- State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015-23.Health affairs (Project Hope) · 2025Article
- Predictors of Medicaid managed care plan performance on opioid use disorder treatment quality metrics.Drug and alcohol dependence · 2025Article
- Barriers to accessing medications for opioid use disorder among rural individuals.The International journal on drug policy · 2025Article
- Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug and alcohol dependence · 2025Article
- Prescribing of extended release buprenorphine injection for Medicaid beneficiaries, 2018-2022.Addiction (Abingdon, England) · 2024Article
- Buprenorphine use among non-hospital residential programs.Drug and alcohol dependence · 2024Article
- Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims.Addiction science & clinical practice · 2024Observational
- Use of in-network insurance benefits is critical for improving retention in telehealth-based buprenorphine treatment.Health affairs scholar · 2024Article
- US payment policy for medications to treat opioid use disorder: landscape and opportunities.Health affairs scholar · 2024Article
- Low-Threshold Buprenorphine in Non-Traditional Settings: A Scoping Review.Substance use : research and treatmentReview
- Medication Assisted Treatment Program Policies: Opinions of People in Treatment.Journal of primary care & community healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Buprenorphine is a treatment medication that decreases mortality risks among people with opioid use disorder (OUD). Despite its efficacy, buprenorphine is underused in the US. Insurance restrictions are commonly cited as barriers to buprenorphine prescribing. Using Medicaid, Medicare Advantage, and commercial insurance formulary files, we examined insurance-imposed utilization restrictions for buprenorphine for OUD for each year from 2017 to 2021 by insurance type. Almost all plans covered immediate-release buprenorphine in 2021, with a general trend of decreasing prior authorization requirements and quantity limits since 2017. In contrast, two payers had relatively low coverage of extended-release buprenorphine, with only 46 percent of commercial plans and only 19 percent of Medicare Advantage plans covering this formulation. Even though most Medicaid plans covered extended-release buprenorphine in 2021, 37 percent required prior authorization. Policy makers and researchers concerned with buprenorphine insurance barriers should shift their attention to extended-release buprenorphine. State lawmakers could help address these barriers by mandating that insurers include extended-release buprenorphine on their preferred drug lists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.